NBC News NOW Takes a Positive Approach to News

NBC News NOW is the newest addition to the news cycle. Have Americans grown tired of the negative & angry, 24/7 news cycle? NBC thinks so.

The NBC News NOW focus is not ‘click-bait’ sensational headlines; instead, it believes people need a news atmosphere designed not to leave them angry and divided. Unlike some competitive news outlet websites set up in a tabloid, sensationalized way to capitalize on the discourse, one visit to the NBC News NOW page and the differences are noticeable. The news layout is straightforward, and people can get the information they want without the alarm bells.

There’s no secret to NBC’s news approach; it’s by design. NBC News president Noah Oppenheim told Poynter in a January 2022 interview, “NBC News’ mission is to hold the middle ground and be objective and nonpartisan.”

This objective approach to news and journalism is music to the ears of Darren Campo, Adjunct Professor at NYU Stern School of Business.

Darren’s Thoughts

“It’s all about a pleasant environment, this is a great product that puts the viewer first and creates an upbeat environment that doesn’t drain the viewer like a lot of other news streams. Think of the relationship that NBC has in all of the areas that we call news, whether it’s with the Today Show, which covers pop culture, hard news on the nightly news politics with Meet the Press, breaking news on MSNBC, and Business News on CNBC. And all of this is being supported by local news operations in the affiliate news operations. The big lesson is that NBC News being ubiquitous in all forms of linear is able to bring the best of those resources to streaming. But I also think one of the big lessons is that NBC News now knows that although it’s in the news business, it’s also in the mood-raising business, not the anger and outrage-building business.

So it creates a very pleasantly consistent experience from both talent and editorial that works really well for the viewers and for revenues. It’s terrific because it creates a premium environment for advertisers and a news product.”

Article by James Kent

 

 

 

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More